Distorted relation between mRNA copy number and corresponding major histocompatibility complex ligand density on the cell surface

Molecular and Cellular Proteomics

Volumn 6, Issue 1, 2007, Pages 102-113

  Weinzierl, Andreas O ^a   Lemmel, Claudia ^a   Schoor, Oliver ^a   Müller, Margret ^a   Krüger, Tobias ^a   Wernet, Dorothee ^a   Hennenlotter, Jörg ^a   Stenzl, Arnulf ^a   Klingel, Karin ^a   Rammensee, Hans Georg ^a   Stevanović, Stefan ^a,b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b Proteome Center Tübingen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; LIGAND; MAJOR HISTOCOMPATIBILITY ANTIGEN; MESSENGER RNA; TRANSCRIPTOME; TUMOR ANTIGEN;

ARTICLE; CELL DENSITY; CELL SURFACE; CONTROLLED STUDY; CORRELATION ANALYSIS; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; KIDNEY CARCINOMA; KIDNEY PARENCHYMA; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUANTITATIVE ANALYSIS; RNA ANALYSIS; RNA TRANSLATION; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; GENE DOSAGE; HLA ANTIGENS; HUMANS; KIDNEY; LIGANDS; MAJOR HISTOCOMPATIBILITY COMPLEX; MOLECULAR SEQUENCE DATA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; RNA, MESSENGER;

EID: 33846534321     PISSN: 15359476     EISSN: None     Source Type: Journal    
DOI: 10.1074/mcp.M600310-MCP200     Document Type: Article

References (42)

1. Admon, A., Barnea, E., and Ziv, T. (2003) Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides. Mol. Cell. Proteomics 2, 388-398
2. Gygi, S. P., Rochon, Y., Franza, B. R., and Aebersold, R. (1999) Correlation between protein and mRNA abundance in yeast. Mol. Cell. Biol. 19, 1720-1730
3. Princiotta, M. F., Finzi, D., Qian, S. B., Gibbs, J., Schuchmann, S., Buttgereit, F., Bennink, J. R., and Yewdell, J. W. (2003) Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 18, 343-354
4. Washburn, M. P., Koller, A., Oshiro, G., Ulaszek, R. R., Plouffe, D., Deciu, C., Winzeler, E., and Yates, J. R., III (2003) Protein pathway and complex clustering of correlated mRNA and protein expression analyses in Saccharomyces cerevisiae. Proc. Natl. Acad. Sci. U. S. A. 100, 3107-3112
5. Falk, K., Rotzschke, O., Stevanovic, S., Jung, G., and Rammensee, H. G. (1991) Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules. Nature 351, 290-296
6. Zinkernagel, R. M., and Doherty, P. C. (1974) Immunological surveillance against altered self components by sensitised T lymphocytes in lymphocytic choriomeningitis. Nature 251, 547-548
7. Wolfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer zum Buschenfelde, K. H., and Boon, T. (1994) Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes. Eur. J. Immunol 24, 759-764
8. Rammensee, H. G., Weinschenk, T., Gouttefangeas, C., and Stevanovic, S. (2002) Towards patient-specific tumor antigen selection for vaccination. Immunol. Rev. 188, 164-176
9. Weinschenk, T., Gouttefangeas, C., Schirle, M., Obermayr, F., Walter, S., Schoor, O., Kurek, R., Loeser, W., Bichler, K. H., Wernet, D., Stevanovic, S., and Rammensee, H. G. (2002) Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. 62, 5818-5827
10. Yajima, N., Yamanaka, R., Mine, T., Tsuchiya, N., Homma, J., Sano, M., Kuramoto, T., Obata, Y., Komatsu, N., Arima, Y., Yamada, A., Shigemori, M., Itoh, K., and Tanaka, R. (2005) Immunologic evaluation of personalized peptide vaccination for patients with advanced malignant glioma. Clin. Cancer Res. 11, 5900-5911
11. Hanash, S., Brichory, F., and Beer, D. (2001) A proteomic approach to the identification of lung cancer markers. Dis. Markers 17, 295-300
12. van der Bruggen, P., Traversari, C., Chomez, P., Lurquin, C., De Plaen, E., Van den Eynde, B., Knuth, A., and Boon, T. (1991) A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254, 1643-1647
13. Takahashi, M., Rhodes, D. R., Furge, K. A., Kanayama, H., Kagawa, S., Haab, B. B., and Teh, B. T. (2001) Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc. Natl. Acad. Sci. U. S. A. 98, 9754-9759
14. Mathiassen, S., Lauemoller, S. L., Ruhwald, M., Claesson, M. H., and Buus, S. (2001) Tumor-associated antigens identified by mRNA expression profiling induce protective anti-tumor immunity. Eur. J. Immunol. 31, 1239-1246
15. Baumeister, W., Walz, J., Zuhl, F., and Seemuller, E. (1998) The proteasome: paradigm of a self-compartmentalizing protease. Cell 92, 367-380
16. Yewdell, J. W., Anton, L. C., and Bennink, J. R. (1996) Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J. Immunol. 157, 1823-1826
17. Schubert, U., Anton, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., and Bennink, J. R. (2000) Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature 404, 770-774
18. Shepherd, J. C., Schumacher, T. N., Ashton-Rickardt, P. G., Imaeda, S., Ploegh, H. L., Janeway, C. A., Jr., and Tonegawa, S. (1993) TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 74, 577-584
19. Serwold, T., Gonzalez, F., Kim, J., Jacob, R., and Shastri, N. (2002) ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 419, 480-483
20. Gaczynska, M., Rock, K. L., and Goldberg, A. L. (1993) γ-Interferon and expression of MHC genes regulate peptide hydrolysis by proteasomes. Nature 365, 264-267
21. Hisamatsu, H., Shimbara, N., Saito, Y., Kristensen, P., Hendil, K. B., Fujiwara, T., Takahashi, E., Tanahashi, N., Tamura, T., Ichihara, A., and Tanaka, K. (1996) Newly identified pair of proteasomal subunits regulated reciprocally by interferon γ. J. Exp. Med. 183, 1807-1816
22. Banchereau, J., Palucka, A. K., Dhodapkar, M., Burkeholder, S., Taquet, N., Rolland, A., Taquet, S., Coquery, S., Wittkowski, K. M., Bhardwaj, N., Pineiro, L., Steinman, R., and Fay, J. (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458
23. Slingluff, C. L., Jr., Petroni, G. R., Yamshchikov, G. V., Hibbitts, S., Grosh, W. W., Chianese-Bullock, K. A., Bissonette, E. A., Barnd, D. L., Deacon, D. H., Patterson, J. W., Parekh, J., Neese, P. Y., Woodson, E. M., Wiernasz, C. J., and Merrill, P. (2004) Immunologic and clinical outcomes of vaccination with a multiepitope melanoma peptide vaccine plus low-dose interleukin-2 administered either concurrently or on a delayed schedule. J. Clin. Oncol. 22, 4474-4485
24. Boer, J. M., Huber, W. K., Sultmann, H., Wilmer, F., von Heydebreck, A., Haas, S., Korn, B., Gunawan, B., Vente, A., Fuzesi, L., Vingron, M., and Poustka, A. (2001) Identification and classification of differentially expressed genes in renal cell carcinoma by expression profiling on a global human 31,500-element cDNA array. Genome Res. 11, 1861-1870
25. Lovisolo, J. A., Casati, B., Clerici, L., Marafante, E., Bono, A. V., Celato, N., and Salvadore, M. (2006) Gene expression profiling of renal cell carcinoma: a DNA macroarray analysis. BJU Int. 98, 205-216
26. Lemmel, C., Weik, S., Eberle, U., Dengjel, J., Kratt, T., Becker, H. D., Rammensee, H. G., and Stevanovic, S. (2004) Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling. Nat. Biotechnol. 22, 450-454
27. Schirle, M., Keilholz, W., Weber, B., Gouttefangeas, C., Dumrese, T., Becker, H. D., Stevanovic, S., and Rammensee, H. G. (2000) Identification of tumor-associated MHC class I ligands by a novel T cell-independent approach. Eur. J. Immunol. 30, 2216-2225
28. Weinzierl, A. O., and Stevanovic, S. (2006) LC-MS-based protein and peptidequantification using stable isotope labels: from ICAT in general to differential N-terminall coding (dNIC in particular, in Biotechnology and Genetic Engineering Reviews (Harding, S. E., ed) Vol. 23, pp 21-39, Lavoisier/Intercept, Cachan, France
29. Krüger, T., Schoor, O., Lemmel, C., Kraemer, B., Reichle, C., Dengjel, J., Weinschenk, T., Muller, M., Hennenlotter, J., Stenzi, A., Rammensee, H. G., and Stevanovic, S. (2005) Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol. Immunother. 54, 826-836
30. Gastl, G., Ebert, T., Finstad, C. L., Sheinfeld, J., Gomahr, A., Aulitzky, W., and Bander, N. H. (1996) Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon γ. J. Urol. 155, 361-367
31. Toes, R. E., Nussbaum, A. K., Degermann, S., Schirle, M., Emmerich, N. P., Kraft, M., Laplace, C., Zwinderman, A., Dick, T. P., Muller, J., Schonfisch, B., Schmid, C., Fehling, H. J., Stevanovic, S., Rammensee, H. G., and Schild, H. (2001) Discrete cleavage motifs of constitutive and immunoproteasomes revealed by quantitative analysis of cleavage products. J. Exp. Med. 194, 1-12
32. Basler, M., Youhnovski, N., Van Den Broek, M., Przybylski, M., and Groettrup, M. (2004) Immunoproteasomes down-regulate presentation of a subdominant T cell epitope from lymphocytic choriomeningitis virus. J. Immunol. 173, 3925-3934
33. Chapiro, J., Claverol, S., Piette, F., Ma, W., Stroobant, V., Guillaume, B., Gairin, J. E., Morel, S., Burlet-Schiltz, O., Monsarrat, B., Boon, T., and Van den Eynde, B. J. (2006) Destructive cleavage of antigenic peptides either by the immunoproteasome or by the standard proteasome results in differential antigen presentation. J. Immunol. 176, 1053-1061
34. Van der Bruggen, P., and Van den Eynde, B. J. (2006) Processing and presentation of tumor antigens and vaccination strategies. Curr. Opin. Immunol. 18, 98-104
35. Hammer, G. E., Gonzalez, F., Champsaur, M., Cado, D., and Shastri, N. (2006) The aminopeptidase ERAAP shapes the peptide repertoire displayed by major histocompatibility complex class I molecules. Nat Immunol. 7, 103-112
36. Yewdell, J. W. (2005) The seven dirty little secrets of major histocompatibility complex class I antigen processing. Immunol. Rev. 207, 8-18
37. Schmidt, S. M., Schag, K., Muller, M. R., Weinschenk, T., Appel, S., Schoor, O., Weck, M. M., Grunebach, F., Kanz, L., Stevanovic, S., Rammensee, H. G., and Brossart, P. (2004) Induction of adipophilin-specific cytotoxic T lymphocytes using a novel HLA-A2-binding peptide that mediates tumor cell lysis. Cancer Res. 64, 1164-1170
38. Milner, E., Barnea, E., Beer, I., and Admon, A. (2006) The turnover kinetics of major histocompatibility complex peptides of human cancer cells. Mol. Cell. Proteomics 5, 357-365
39. van Hall, T., Sijts, A., Camps, M., Offringa, R., Melief, C., Kloetzel, P. M., and Ossendorp, F. (2000) Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. J. Exp. Med. 192, 483-494
40. Atkins, D., Ferrone, S., Schmahl, G. E., Storkel, S., and Seliger, B. (2004) Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? J. Urol. 171, 885-889
41. Yewdell, J. W., Schubert, U., and Bennink, J. R. (2001) At the crossroads of cell biology and immunology: DRiPs and other sources of pepticle ligands for MHC class I molecules. J. Cell Sci. 114, 845-851
42. Scheel, B., Aulwurm, S., Probst, J., Stitz, L., Hoerr, I., Rammensee, H. G., Weller, M., and Pascolo, S. (2006) Therapeutic anti-tumor immunity triggered by injections of immunostimulating single-stranded RNA. Eur. J. Immunol. 36, 2807-2816